Diminished social interaction incentive contributes to social deficits in mouse models of autism spectrum disorder

One of the core symptoms of autism spectrum disorder (ASD) is impaired social interaction. Currently, no pharmacotherapies exist for this symptom due to complex biological underpinnings and distinct genetic models which fail to represent the broad disease spectrum. One convincing hypothesis explaining social deficits in human ASD patients is amotivation, however it is unknown whether mouse models of ASD represent this condition. Here we used two highly trusted ASD mouse models (male Shank3‐deficient [Shank3^+/ΔC] mice modeling the monogenic etiology of ASD, and inbred BTBR mice [both male and female] modeling the idiopathic and highly polygenic pathology for ASD) to evaluate the level of motivation to engage in a social interaction. In the behavioral paradigms utilized, a social stimulus was placed in the open arm of the elevated plus maze (EPM), or the light compartment of the light‐dark box (LDB). To engage in a social interaction, mice were thus required to endure innately aversive conditions (open areas, height, and/or light). In the modified EPM paradigm, both Shank3^+/ΔC and BTBR mice demonstrated decreased open‐arm engagement with a social stimulus but not a novel object, suggesting reduced incentive to engage in a social interaction in these models. However, these deficits were not expressed under the less severe aversive pressures of the LDB. Collectively, we show that ASD mouse models exhibit diminished social interaction incentive, and provide a new investigation strategy facilitating the study of the neurobiological mechanisms underlying social reward and motivation deficits in neuropsychiatric disorders.     

Two New Abietane Diterpenoids from Selaginella moellendorffii Hieron.

Two new abietane diterpenoids, (3S,5R,10S)‐3‐hydroxy‐12‐O‐demethyl‐11‐deoxy‐19(4→3)‐abeo‐cryptojaponol, 12,19‐dihydroxyabieta‐8,11,13‐trien‐7‐one, were isolated from Selaginella moellendorffii Hieron., together with one known abietane diterpenoid and four known tetracyclic triterpenoids. Their structures were characterized by their 1D‐ and 2D‐NMR, ECD and mass spectral studies. All compounds were tested for their inhibitory effects on proliferation of three human cancer cells (human non‐small‐cell lung carcinoma cell lines A549 and human breast adenocarcinoma cell lines MDA‐MB‐231 and MCF‐7) in vitro. Among them, three compounds displayed modest cytotoxic activities against the above three human cancer cell lines with IC₅₀ values ranging from 16.28 to 40.67 μM.     

High‐Efficiency CsPbI2Br Perovskite Solar Cells with Dopant‐Free Poly(3‐hexylthiophene) Hole Transporting Layers

CsPbI₂Br is emerging as a promising all‐inorganic material for perovskite solar cells (PSCs) due to its more stable lattice structure and moisture resistance compared to CsPbI₃, although its device performance is still much behind this counterpart. Herein, a preannealing process is developed and systematically investigated to achieve high‐quality CsPbI₂Br films by regulating the nucleation and crystallization of perovskite. The preannealing temperature and time are specifically optimized for a dopant‐free poly(3‐hexylthiophene) (P3HT)‐based device to target dopant‐induced drastic performance degradation for spiro‐OMeTAD‐based devices. The resulting P3HT‐based device exhibits comparable power conversion efficiency (PCE) to spiro‐OMeTAD‐based devices but much enhanced ambient stability with over 95% PCE after 1300 h. A diphenylamine derivative is introduced as a buffer layer to improve the energy‐level mismatch between CsPbI₂Br and P3HT. A record‐high PCE of 15.50% for dopant‐free P3HT‐based CsPbI₂Br PSCs is achieved by alleviating the open‐circuit voltage loss with the buffer layer. These results demonstrate that the preannealing processing together with a suitable buffer layer are applicable strategies for developing dopant‐free P3HT PSCs with high efficiency and stability.     

Hybrid Perovskite‐Organic Flexible Tandem Solar Cell Enabling Highly Efficient Electrocatalysis Overall Water Splitting

Perovskite‐organic tandem solar cells are attracting more attention due to their potential for highly efficient and flexible photovoltaic device. In this work, efficient perovskite‐organic monolithic tandem solar cells integrating the wide bandgap perovskite (1.74 eV) and low bandgap organic active PBDB‐T:SN6IC‐4F (1.30 eV) layer, which serve as the top and bottom subcell, respectively, are developed. The resulting perovskite‐organic tandem solar cells with passivated wide‐bandgap perovskite show a remarkable power conversion efficiency (PCE) of 15.13%, with an open‐circuit voltage (V_oc) of 1.85 V, a short‐circuit photocurrent (J_sc) of 11.52 mA cm^?2, and a fill factor (FF) of 70.98%. Thanks to the advantages of low temperature fabrication processes and the flexibility properties of the device, a flexible tandem solar cell which obtain a PCE of 13.61%, with V_oc of 1.80 V, J_sc of 11.07 mA cm^?2, and FF of 68.31% is fabricated. Moreover, to demonstrate the achieved high V_oc in the tandem solar cells for potential applications, a photovoltaic (PV)‐driven electrolysis system combing the tandem solar cell and water splitting electrocatalysis is assembled. The integrated device demonstrates a solar‐to‐hydrogen efficiency of 12.30% and 11.21% for rigid, and flexible perovskite‐organic tandem solar cell based PV‐driven electrolysis systems, respectively.     

静脉溶栓时机对急性ST段抬高型心肌梗死患者溶栓效果及主要不良心脏事件发生率的影响

目的:探讨静脉溶栓时机对急性ST段抬高型心肌梗死患者溶栓效果及主要不良心脏事件发生率的影响。方法:将2016年1月至2017年12月我院接诊的314例急性ST段抬高型心肌梗死患者纳入本研究,按照溶栓治疗时间不同分为A组(发病至溶栓时间6 h)172例、B组(发病至溶栓时间为6～12 h)102例和C组(发病至溶栓时间12 h)40例,比较三组患者溶栓效果、溶栓后ST段回落情况以及住院期间主要不良心脏事件发生情况。结果:A组患者梗死冠脉溶通率、溶栓后ST段回落幅度高于B组和C组,且B组高于C组,差异均有统计学意义(P0.05)。A组患者治疗后ST段回落最大幅度所需时间、住院期间主要不良心脏事件总发生率低于B组和C组,且B组低于C组,差异均有统计学意义(P0.05)。结论:急性ST段抬高型心肌梗死患者发病后6 h内静脉溶栓治疗梗死冠脉溶通率更高、ST段回落效果更好,可降低住院期间主要不良心脏事件发生风险。     

吡拉西坦联合鼠神经生长因子对急性缺血性脑卒中患者的疗效及Hcy、PCT和皮质醇水平的影响

目的:探讨吡拉西坦联合鼠神经生长因子对急性缺血性脑卒中患者的疗效及对同型半胱氨酸(Hcy)、降钙素原(PCT)和皮质醇水平的影响。方法:回顾性分析我院2017年2月～2018年11月收治的73例急性缺血性脑卒中患者为研究对象,依据入院先后顺序分为对照组(n=35)和观察组(n=38)。对照组患者采用吡拉西坦治疗,观察组基于对照组加以鼠神经生长因子治疗。观察并比较两组临床疗效,治疗前后美国国立卫生研究院卒中量表(NIHSS)、日常生活能力(ADL),治疗前及治疗2周结束时用全自动生化分析仪测定血浆Hcy水平,用放射免疫学分析法测定PCT水平,用化学发光法测定皮质醇水平,用超声多普勒诊断仪测定基底动脉、左右大脑中动脉血流。结果:治疗后,观察组NIHSS评分低于对照组(8.96±1.21)vs(11.27±1.59)分,ADL评分高于对照组(74.21±9.75)vs(66. 04±8.03)分(P0.05)。观察组总有效率高于对照组89.47%vs 68.57%(P0.05)。治疗后,观察组Hcy、PCT及皮质醇水平低于对照组(14.27±2.01)vs (18.51±2.84)μmol/L、(0.25±0.03)vs (0.31±0.04)μg/L、(171.93±23.86)vs(228.75±30.27)nmol/L(P0.05)。治疗后,观察组脑血流学指标高于对照组基底动脉(43.81±6.84)vs(39.62±5.27)mL/min、左大脑中动脉血流(64.27±9.95)vs(57.03±7.52)mL/min、右大脑中动脉血流(62.85±9.01)vs(56.64±7.42)mL/min(P0.05)。结论:吡拉西坦联合鼠神经生长因子能够提高急性缺血性脑卒中的疗效,降低Hcy、PCT及皮质醇水平,促进神经功能的恢复。     

光周期和温度对虎斑蝶卵、幼虫及蛹存活的影响

通过在人工气候箱内设定不同光周期和温度梯度单虫饲养观察个体发育史,研究了光周期和温度对虎斑蝶Danaus genutia幼期存活的影响,研究结果可为该高观赏价值蝶种的规模化养殖提供依据。结果表明,在长光照(L∶D=15∶9)条件下,17.5、20.0、22.5、25.0、27.5、30.0℃时虎斑蝶卵的孵化率分别为63.72%、71.67%、65.75%、75.00%、67.12%、59.56%,幼虫的存活率分别为85.67%、85.96%、91.19%、89.20%、80.86%、68.78%,蛹的存活率分别为82.76%、100.00%、96.00%、97.06%、100.00%、100.00%;在短光照(L∶D=9∶15)条件下,17.5、20.0、25.0、30.0℃时虎斑蝶卵的孵化率分别为86.36%、67.06%、75.00%、77.50%,幼虫的存活率分别为85.05%、84.59%、85.74%、80.78%,蛹的存活率分别为93.30%、94.12%、100.00%、100.00%。结果表明,17.5℃和30.0℃均不利于虎斑蝶幼期的存活,20.0～27.5℃是其幼期生长发育适宜的温度范围。长光照利于幼虫的存活,短光照利于卵的孵化和蛹的羽化;在17.5～30.0℃内,较高的温度利于蛹的羽化,而较低的温度利于卵的孵化和幼虫的存活;温度对虎斑蝶卵的孵化、幼虫的存活及蛹的羽化影响大于光周期;在养殖生产上,建议将幼期养殖温度控制在20.0～27.5℃,幼虫期饲养在长光照下为宜,卵和蛹期置于短光照下为宜。